Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Cancer Res Treat. 2022 Jan;54(1):1-9.
DOI: 10.4143/crt.2021.1115.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469.
DOI: 10.1007/s00432-021-03527-4.
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Cancer Med. 2021 Oct;10(20):7012-7020.
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma
Clin Cancer Res. 2021 Jul 27; clincanres.1061.2021.
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01)
Cancer Res Treat. 2021 Apr 27.
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)
Cytokine Volume 142, June 2021,155487
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
Cancers (Basel). 2021 Jan; 13(2): 331.
